Orexin receptor antagonists - A patent review (2010 to August 2014)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 12, 2014, Pages 1367-1381

  Boss, Christoph ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Addiction; G protein coupled receptors; Insomnia; Neuropeptides; Orexin peptides; Orexin receptors; Sleep

Indexed keywords

ACT 462206; AGENTS AFFECTING PROTEIN METABOLISM; ALMOREXANT; FILOREXANT; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; OREXIN RECEPTOR ANTAGONIST; SUVOREXANT; UNCLASSIFIED DRUG; OREXIN RECEPTOR;

AROUSAL; CIRCADIAN RHYTHM; DRUG APPROVAL; DRUG INDICATION; EMOTION; HUMAN; INSOMNIA; NONHUMAN; PATENT; PRIMARY INSOMNIA; REM SLEEP; REVIEW; STEREOCHEMISTRY; WAKEFULNESS; ANIMAL; ANTAGONISTS AND INHIBITORS; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; OREXIN RECEPTORS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84911154996     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.978859     Document Type: Review

References (131)

1. Gatfield J, Brisbare-Roch C, Jenck F, et al. Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 2010;5:1197-214
2. deLecca L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-7
3. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85
4. Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52:891-903
5. Matsuki T, Sakurai T. Orexins and orexin receptors: from molecules to integrative physiology. Results Probl Cell Differ 2008;46:27-55
6. Randeva HS, Karteris E, Grammatopoulos D, et al. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J Clin Endocrinol Metab 2001;86:4808-13
7. Nilaweera KN, Barrett P, Mercer JG, Morgan PJ. Precursor-protein convertase 1 gene expression in the mouse hypothalamus: differential regulation by ob gene mutation, energy deficit and administration of leptin, and coexpression with prepro-orexin. Neuroscience 2003;119:713-20
8. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015
9. Marcus JN, Aeschkenasi CE, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6-25
10. Mieda M, Hasegawa E, Kisanuki YY, et al. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 2011;31:6518-26
11. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7
12. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
13. Cheminelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51
14. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76
15. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38:715-30
16. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40
17. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62
18. Smith MI, Piper DC, Duxon MS, et al. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci Lett 2003;341:256-8
19. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5
20. Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93
21. Coleman PJ, Schreier JD, Cox CD, et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012;7:415-24
22. Boss C, Brisbare-Roch C, Jenck F, et al. Orexin receptor antagonism: a new principle in neuroscience Chimia. 2008;62:974-9
23. Dingemanse J, Dorffner G, Hajak G, et al. Proof-of-concept study in primary insomnia patients with ACT-078573, a dual orexin receptor antagonist (Abstract). Sleep Biol Rhythms 2007;5:A194
24. Neubauer DN. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Invest Drugs 2010;11:101-10
25. Dugovic C, Shelton J, Sutton S, et al. Sleep-inducing effects mediated by selective blockade of orexin OX2 receptors during the light phase in the rat (Abstract). Sleep 2008;31:A33
26. Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330:142-51
27. Etori K, Saito Y C, Tsujino N. Sakurai, T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front Neurosci 2014;8:8-1-13
28. Yamanaka T, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003;38:701-13
29. Sakurai T. Orexin: a link between energy homeostasis and adaptive behaviour. Curr Opin Clin Nutr Metab Care 2003;6:353-60
30. Berthoud HR. Mind versus metabolism in the control of food intake and energy balance. Physiol Behav 2004;81:781-93
31. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006;443:289-95
32. Siegel JM, Boehmer LN. Narcolepsy and the hypocretin system - where motion meets emotion. Nat Clin Pract Neurol 2006;2:548-56
33. Geerling JC, Mettenleiter TC, Loewy AD. Orexin neurons project to diverse sympathetic outflow systems. Neuroscience 2003;122:541-50
34. Zhang W, Sakurai T, Fukuda Y, et al. Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. Regul Integr Comp Physiol 2006;290:R1654-63
35. Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med 2010;16:111-15
36. Aston-Jones G, Smith RJ, Sartor GC, et al. Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res 2010;1314:74-90
37. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005;437:556-9
38. Steiner MA, Gatfield J, Brisbare-Roch C, et al. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 2013;8:898-903
39. Heinonen MV, Purhonen AK, Makela KA, et al. Functions of orexins in peripheral tissues. Acta Physiol 2008;192:471-85
40. Malherbe P, Borroni E, Pinard E, et al. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol 2009;76(3):618-31
41. Dugovic C, Shelton JE, Leah E A, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;1):142-51
42. Di Fabio R; Glaxo Group Limited. WO2011023585; 2011
43. Di Fabio R; Glaxo Group Limited. WO2011023578; 2011
44. Alvaro G, Amantini D; Glaxo Group Limited. WO2010072722; 2010
45. Alvaro G, Amantini D, Belvedere S; Glaxo Group Limited. WO2010060472; 2010
46. Alvaro G, Amantini D, Belvedere S; Glaxo Group Limited. WO2010060470; 2010
47. Alvaro G, Amantini D, Belvedere S; Glaxo Group Limited. WO2010060471; 2010
48. Alvaro G, Amantini D, Castiglioni E, et al. Glaxo Group Limited. WO2010063663; 2010
49. Di Fabio R; Glaxo Group Limited. WO2012089606; 2012
50. Alvaro G, Amantini D, Castiglioni E, et al. Glaxo Group Limited. WO2010063662; 2010
51. Amantini D, Di Fabio R; Glaxo Group Limited. WO2010122151; 2010
52. Di Fabio R; Glaxo Group Limited. WO2012089607; 2012
53. Behnke D, Betschart C, Cotesta S, et al. Novartis AG. WO2011073316; 2011
54. Behnke D, Betschart C, Cotesta S, et al. Novartis AG. WO2010086366; 2010
55. Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2011076744,2011
56. Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2012055888; 2012
57. Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2011076747; 2011
58. Badiger S, Behnke D, Betschart C, et al. Novartis AG. WO2012101487; 2012
59. Betschart C, Hintermann S, Behnke D, et al. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 2013;56:7590-607
60. Cox CD, Fraley ME, Schreier J; Merck Sharp & Dohme Corp. WO2010048017; 2010
61. Breslin MJ, Coleman PJ, Cox CD, et al. Merck Sharp & Dohme Corp. WO2010048010; 2010
62. Cox CD, Coleman PJ, Breslin MJ, et al. Merck Sharp & Dohme Corp. WO2010048012; 2010
63. Cox CD, Coleman P J, Flores B, et al. Merck Sharp & Dohme Corp. WO2010048013; 2010
64. Kuduk SD, Skudlarek J W; Merck Sharp & Dohme Corp. WO2013059222; 2013
65. Cox CD, Coleman OJ, Schreier JD; Merck Sharp & Dohme Corp. WO2010048014; 2010
66. Cox CD, Flores B, Schreier JD; Merck Sharp & Dohme Corp. WO2010048016; 2010
67. Kuduk SD, Di Marco C; Merck Sharp & Dohme Corp. WO2013059163; 2013
68. Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2013062857; 2013
69. Kuduk SD, Skudlarek JW, Di Marco CN, et al. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorg Med Chem Lett 2014;24:1784-9
70. Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014062533; 2014
71. Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014066196; 2014
72. Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014085208; 2014
73. Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014099696; 2014
74. Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014099697; 2014
75. Kuduk SD, Skudlarek JW; Merck Sharp & Dohme Corp. WO2014099698, 2014
76. Kuduk SD, Cooke A, Stump C; Merck Sharp & Dohme Corp. WO2014113303, 2014
77. Branstetter BJ, Letavic MA, Ly KS, et al. Janssen Pharmaceutica NV. WO2011050200, 2011
78. Roecker AJ, Mercer SP, Schreier JD, et al. Discovery of 5″-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2′:5′,3″-terpyridine-3′-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22
79. Roecker AJ, Reger TS, Mattern MC, et al. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90
80. Coleman PJ, Mercer SP, Reger TS, et al. Merck Sharp & Dohme Corp. WO2010017260, 2010
81. Bergman JM, Coleman PJ, Mattern MC, et al. Merck Sharp & Dohme Corp. WO2010051236, 2010
82. Bergman JM, Coleman PJ, Roecker AJ, et al. Merck Sharp & Dohme Corp. WO2010051237, 2010
83. Coleman PJ, Cox CD, Mercer SP, et al. Merck Sharp & Dohme Corp. WO2010051238, 2010
84. Mercer SP, Roecker AJ; Merck Sharp & Dohme Corp. WO2010141275, 2010
85. Mercer SP, Roecker AJ; Merck Sharp & Dohme Corp. WO2011005636, 2011
86. Li D, Roecker AJ; Merck Sharp & Dohme Corp. WO2013062858; 2013
87. Coleman PJ, Mercer SP, Roecker AJ; Merck Sharp & Dohme Corp. WO2011053522, 2011
88. Chai W, Letavic M A, Ly K S, et al. Janssen Pharmaceutica NV. WO2011050198; 2011
89. Letavic MA, Rudolph DA, Savall BM, et al. Janssen Pharmaceutica NV. WO2012145581; 2012
90. Branstetter BJ, Letavic MA, Ly KS, et al. Janssen Pharmaceutica NV. WO2011050202; 2011
91. Terauchi T, Takemura A, Doko T, et al. Eisai R & D Management Co., Ltd. WO2012039371; 2012
92. Oi N, Suzuki M, Terauchi T, et al. Synthesis and evaluation of novel radioligands for positron emission tomography imaging of the orexin-2 receptor. J Med Chem 2013;56:6371-85
93. Nozawa D, Suzuki R, Futamura A, et al. Taisho Pharmaceutical Co. WO2012081692; 2012
94. Suzuki R, Futamura A, Abe M, et al. Taisho Pharmaceutical Co. WO2012153729; 2012
95. Araki Y, Nozawa D, Zuki R, et al. Taisho Pharmaceutical Co. WO2013187466; 2013
96. Futamura A, Araki Y, Abe M, et al. Taisho Pharmaceutical Co. WO2013187467; 2013
97. Abe M, Futamura A, Suzuki R, et al. Taisho Pharmaceutical Co. WO2013005755; 2013
98. Ohta H, Abe M; Taisho Pharmaceutical Co. WO2014091876; 2014
99. Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010044054; 2010
100. Bentley JM, Davenport T, Slack M, Evotec AG. WO2011138265; 2011
101. Bentley JM, Davenport T, Hallett DJ, Evotec AG. WO2011138266; 2011
102. Knust H, Nettekoven M, Pinard E, et al. F. Hoffmann-La Roche AG. WO2010012620; 2010
103. Bingham MJ, Dunbar NA, Huggett M J, et al. N.V. Organon. WO2011061318; 2011
104. Kamenecka T, Jiang R, Song X; Eolas Therapeutics Inc. WO2013119639; 2013
105. Aissaoui H, Boss C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2009016560; 2009
106. Aissaoui H, Boss C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2009016564; 2009
107. Aissaoui H, Boss C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2009004584; 2009
108. Branch CL, Nash DJ, Stemp G; GlaxoSmith Kline. WO2003051368; 2003
109. Drahl C. To dream, perchance of sleep. Chem Eng News 2014;92(35):52-5
110. Congreve MS, Christopher JA, Tehan BG, et al. WO2014006402; 2014
111. Stasi LP, Rovati L; Rottapharm S.P.A. WO2011006960; 2011
112. Stasi LP, Rovati LC, Artusi R, et al. Rottapharm S.P.A. WO2013092893; 2013
113. Stasi LP, Rovati L; Rottapharm S.P.A. WO2013139730; 2013
114. Stasi LP, Rovati L, Artusi R, et al. Rottapharm S.P.A. WO2013127913; 2013
115. Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010038200; 2010
116. Aissaoui H, Boss C, Hazemann J, et al. Actelion Pharmaceuticals Ltd. WO2010004507; 2010
117. Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010131191; 2010
118. Aissaoui H, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2010131192; 2010
119. Aissaoui H, Boss C, Brotshci C, et al. Actelion Pharmaceuticals Ltd. WO2012063207; 2012
120. Sifferlen T, Boller A, Chardonneau A, et al. Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1. Bioorg Med Chem Lett 2014;24:1201-8
121. Boss C, Brotschi C, Gatfield J, et al. Actelion Pharmaceuticals Ltd. WO2012025877; 2012
122. Hoch M, va Gorsel H, van Greven J, Dingemanse J. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant. J Clin Pharm 2014;54(9):979-86
123. Boss C, Roch-Brisbare C, Steiner MA, et al. Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist. ChemMedChem 2014;9. [Epub ahead of print]
124. Boss C, Brotschi C, Heidmann B, et al. Actelion Pharmaceuticals Ltd. WO2012085852; 2012
125. Boss C, Brotschi C, Heidmann B, et al. Actelion Pharmaceuticals Ltd. WO2012085857; 2012
126. Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2012110986; 2012
127. Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2012114252; 2012
128. Boss C, Brotschi C, Heidmann B, et al. Actelion Pharmaceuticals Ltd. WO2013050938; 2013
129. Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2013068935; 2013
130. Boss C, Brotschi C, Gude M, et al. Actelion Pharmaceuticals Ltd. WO2013182972; 2013
131. Bolli M, Boss C, Brotschi C, et al. Actelion Pharmaceuticals Ltd. WO2014057435; 2014